Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 749 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension, Pulmonary Clear all

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Home hospital care; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Infections, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulation, Diabetes and Its Complications, End of Life/Desires Only Medical Management
Interventions: Home Hospital care, Traditional Hospital care; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Quincy, Illinois • Hazard, Kentucky

Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions: inhaled mosliciguat, Dry Powder Inhaler; Drug · Device
Lead sponsor: Pulmovant, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Santa Barbara, California • Torrance, California • Kissimmee, Florida + 10 more

Conditions: Pediatric Pulmonary Hypertension
Interventions: No interventions / observations only; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 8 Years to 14 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Aurora, Colorado

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil diethanolamine; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 7 Years to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: COVID-19, Long COVID
Interventions: MouthLabTM; Device
Lead sponsor: Edith Nourse Rogers Memorial Veterans Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Bedford, Massachusetts

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions: 15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution, 120 mg sodium nitrite inhalation solution, 25% MTD sodium nitrite inhalation solution; Drug
Lead sponsor: Aires Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 56 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cardiovascular Diseases
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 15 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Hyperpolarized Xe129; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Intrahepatic Cholangiocarcinoma (Icc)
Interventions: EXOMIC small RNA sequencing, EXOMIC assay (qRT-PCR validation); Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Diabetes, Heart Disease, Hypertension
Interventions: CARIÑO Project, Enhanced Usual Care; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Portopulmonary Hypertension, Pulmonary Hypertension, Cirrhosis, Liver
Interventions: Ambrisentan Pill, Tadalafil Pill; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Interventions: Semaglutide Pen Injector; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Congenital Disorders
Interventions: Not listed
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: Up to 8 Days
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pulmonary Arterial Hypertension, Insulin Resistance
Interventions: Nutrition and Exercise; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pulmonary Arterial Hypertension
Interventions: JNJ-67896049; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: La Jolla, California • Anderson, South Carolina • Dallas, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: QCC374, Placebo Matching; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 5 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension Associated With Connective Tissue Disease, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder), Pulmonary Arterial Hypertension of Congenital Heart Disease, Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension
Interventions: Saliva sample, Health surveys; Genetic · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Pulmonary Hypertension, Pulmonary Artery Pressure, Exercise Performance, Air Pollution
Interventions: sildenafil, placebo; Drug · Other
Lead sponsor: Marywood University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Scranton, Pennsylvania

Conditions: Portopulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: Not listed
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 1 more

Search by objective public record fields.

Rural Home Hospital: Proof of Concept

Rural Hospital-Level Care at Home for Acutely Ill Adults

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Actigraphy in Pediatric Pulmonary Hypertension

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients

Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

Identification of Genetic Markers for Cardiopulmonary Diseases (Genotype)

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension

Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.

Miami Healthy Heart Initiative a Behavioral Study on Cardiovascular Risk Factors

Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension

Feasibility of Semaglutide in Advanced Lung Disease

Pulmonary Hypertension in Trisomy 21 Patients

Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)

A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension

Spironolactone for Pulmonary Arterial Hypertension

Rutgers University Study of the Genetics of Pulmonary Hypertension

Does Sildenafil Increase Exercise Performance in Air Pollution?

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension